Aralez Pharma (ARLZ) Misses Q2 EPS by 2c

Aralez Pharma (NASDAQ: ARLZ) reported Q2 EPS of ($0.42), $0.02 worse than the analyst estimate of ($0.40). Revenue for the quarter came in at $27.6 million versus the consensus estimate of $21.24 million.

For earnings history and earnings-related data on Aralez Pharma (ARLZ) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M